These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31525483)

  • 1. A Survey of Chemoprophylaxis Techniques in Spine Surgery Among American Neurosurgery Training Programs.
    Macki M; Haider SA; Anand SK; Fakih M; Elmenini J; Suryadevara R; Chang V
    World Neurosurg; 2020 Jan; 133():e428-e433. PubMed ID: 31525483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic Low-Molecular-Weight Heparin Versus Unfractionated Heparin in Spine Surgery (PLUSS): A Pilot Matched Cohort Study.
    Macki M; Haddad Y; Suryadevara R; Dabaja AL; Chedid M; Chang V;
    Neurosurgery; 2021 Nov; 89(6):1097-1103. PubMed ID: 34634115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determining the impact of culture on venous thromboembolism prevention in trauma patients: A Southwestern Surgical Congress Multicenter trial.
    Regner JL; Shaver CN;
    Am J Surg; 2019 Jun; 217(6):1030-1036. PubMed ID: 30503515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A tale of two centers: Is low-molecular-weight heparin really superior for prevention of posttraumatic venous thromboembolism?
    Checchi KD; Costantini TW; Badiee J; Berndtson AE; Calvo RY; Rooney AS; Wessels LE; Prieto JM; Sise CB; Sise MJ; Martin MJ; Bansal V
    J Trauma Acute Care Surg; 2021 Sep; 91(3):537-541. PubMed ID: 33901051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Risk of Symptomatic Venous Thromboembolism After Surgery for Spine Metastatic Bone Lesions: A Retrospective Study.
    Groot OQ; Ogink PT; Paulino Pereira NR; Ferrone ML; Harris MB; Lozano-Calderon SA; Schoenfeld AJ; Schwab JH
    Clin Orthop Relat Res; 2019 Jul; 477(7):1674-1686. PubMed ID: 31135550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry.
    Spyropoulos AC; Turpie AG; Dunn AS; Spandorfer J; Douketis J; Jacobson A; Frost FJ;
    J Thromb Haemost; 2006 Jun; 4(6):1246-52. PubMed ID: 16706967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A direct comparison of prophylactic low-molecular-weight heparin versus unfractionated heparin in neurosurgery: A meta-analysis.
    Macki M; Fakih M; Anand SK; Suryadevara R; Elmenini J; Chang V
    Surg Neurol Int; 2019; 10():202. PubMed ID: 31768282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
    Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer.
    Van Matre ET; Reynolds PM; MacLaren R; Mueller SW; Wright GC; Moss M; Burnham EL; Ho PM; Vandivier RW; Kiser TH
    J Thromb Haemost; 2018 Dec; 16(12):2492-2500. PubMed ID: 30347498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of low-molecular-weight heparin versus unfractionated heparin for thromboembolism prophylaxis for medical patients.
    Rothberg MB; Pekow PS; Lahti M; Lindenauer PK
    J Hosp Med; 2012; 7(6):457-63. PubMed ID: 22473716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low molecular weight heparin and unfractionated heparin for prevention of thrombo-embolism in general surgery: a meta-analysis of randomised clinical trials.
    Palmer AJ; Schramm W; Kirchhof B; Bergemann R
    Haemostasis; 1997; 27(2):65-74. PubMed ID: 9212354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV; Howes J; Sharma V; Kadziola Z
    Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial.
    Kakkar VV; Boeckl O; Boneu B; Bordenave L; Brehm OA; Brücke P; Coccheri S; Cohen AT; Galland F; Haas S; Jarrige J; Koppenhagen K; LeQuerrec A; Parraguette E; Prandoni P; Roder JD; Roos M; Rüschemeyer C; Siewert JR; Vinazzer H; Wenzel E
    World J Surg; 1997 Jan; 21(1):2-8; discussion 8-9. PubMed ID: 8943170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.
    Harenberg J; Schmidt JA; Koppenhagen K; Tolle A; Huisman MV; Büller HR
    Thromb Haemost; 2000 May; 83(5):652-6. PubMed ID: 10823256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-molecular weight vs. unfractionated heparin for prevention of venous thromboembolism in general surgery: a meta-analysis.
    Nair P; Trivedi R; Hu P; Zhang Y; Merchant AM
    Updates Surg; 2021 Feb; 73(1):75-83. PubMed ID: 32880870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer.
    Akl EA; Kahale L; Sperati F; Neumann I; Labedi N; Terrenato I; Barba M; Sempos EV; Muti P; Cook D; Schünemann H
    Cochrane Database Syst Rev; 2014 Jun; (6):CD009447. PubMed ID: 24966161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.
    Kirchmaier CM; Wolf H; Schäfer H; Ehlers B; Breddin HK
    Int Angiol; 1998 Sep; 17(3):135-45. PubMed ID: 9821025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-molecular-weight heparin prophylaxis 24 to 36 hours after degenerative spine surgery: risk of hemorrhage and venous thromboembolism.
    Strom RG; Frempong-Boadu AK
    Spine (Phila Pa 1976); 2013 Nov; 38(23):E1498-502. PubMed ID: 23873245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective Analysis of Low-Molecular-Weight Heparin and Unfractionated Heparin in Pediatric Trauma Patients: A Comparative Analysis.
    Culbert MH; Hamidi M; Zeeshan M; Hanna K; Romero A; Joseph B; O'Keeffe T
    J Surg Res; 2020 May; 249():121-129. PubMed ID: 31931398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.